Clinical trial · Observational
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
A Cross-sectional Study Among Healthcare Professionals in Canada to Assess Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures
NCT04567589CI-TRIAL-00047796withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study was cancelled before any data collection due to business reasons.
Summary
Brief summary (as posted)
This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Healthcare Professionals (HCPs).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Fibroids | Uterine Corpus Leiomyoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Percentage of HCPs with correct responses to the knowledge level questions.
- timeFrame
- 18 - 24 months
- description
- Correct responses to knowledge-related questions based on the contents of the Fibristal aRMMs.
Secondary outcomes (4)
- measure
- Percentage of HCPs that recall receiving and reading the HCP Letter and HCP Brochure .
- timeFrame
- 18 - 24 months
- description
- HCP's recall of receiving and reading the HCP Letter and HCP Brochure .
- measure
- Percenatage of HCPs that recall distributing the Fibristal Patient Alert Card
- timeFrame
- 18 - 24 months
- description
- HCP's recall of distributing the Fibristal Patient Alert Card
Eligibility
Eligibility (as posted)
Show eligibility criteria text
Inclusion Criteria: * HCPs have prescribed Fibristal for the indication of uterine fibroids within the past 6 months. * HCPs have provided permission to share their responses in aggregate to Health Canada. Exclusion Criteria: * HCPs who participated in the cognitive pre-testing of the survey questionnaire to be used for the study. * HCPs who have been direct employees of Allergan, ICON, Health Canada, or Professional Targeted Marketing (PTM) within the past 5 years.
References
Publications (0)
Data not yet available
No reference posted for this study.